|Targets||Sphingosine 1 Phosphate Receptor|
|Description||This active molecular is a selective S1P1 receptor agonist that originated by Bristol-Myers Squibb. BMS-520 shows really good efficacy in animal models of arthritis as well as in a mouse EAE (experimental autoimmune encephalomyelitis) model of multiple sclerosis. Agonism of S1P1 has been known to play an important role in lymphocyte trafficking from the thymus and secondary lymphoid organs, resulting in immunosuppression.|
|Synonyms||BMS-520; BMS 520; BMS520. 1-(4-(5-(3-phenyl-4-(trifluoromethyl)isoxazol-5-yl)-1,2,4-oxadiazol-3-yl)benzyl)azetidine-3-carboxylic acid|
|Solubility||Soluble in DMSO|
|Application||Haematological malignancies; Solid tumours|
|Quality Standard||In-house standard|
|Shelf Life||2 month in rt, long time|
|Current Developer||Originator:Bristol-Myers Squibb|
CYM 50260 has been found to be a S1P4 agonist.
CYM 50308 has been found to be an effective and selective S1P4 agonist.
The hydrochloride salt form of PF-543, a novel SphK1 inhibitor that could exhibit activity in induceing necrosis in human colorectal cancer cells in biological ...
Ozanimod, also known as RPC1063, is a selective oral S1P Receptor 1 modulator.
This active moleclar is a Sphingosine 1 Phosphate Receptor antagonists for treatment of multiple sclerosis (MS) and other autoimmune diseases originated by Aren...
The hydrochloride salt form of CYM 50358, which has been found to be an effective S1P4 antagonist.
JTE 013 has been found to be an antagonist of Sphingosine-1-Phosphate Receptor-2 (S1P2R).
This active molecular is a S1P1/S1P5 agonist with limited activity at S1P3. AMG 369 has no activity at S1P2 and S1P4. AMG-369 is shown to reduce blood lymphocyt...